Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.17 (
lysozyme
)
21,489
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human polymorphonuclear leukocytes (PMNs) exhibited a time-dependent (0 to 60 min) increase in the release of
lysozyme
and lactate dehydrogenase (degranulation) when exposed to a static (direct current) magnetic field of 0.1 Tesla. When 1 X 10(6) PMNs were treated with the
calcium channel
antagonists diltiazem, nifedipine, and verapamil before exposure to a magnetic field, no significant change in degranulation was detected compared to control and sham-exposed PMNs that were similarly treated. Likewise, magnetic field-induced inhibition of cell migration was prevented with the addition of these antagonists. Such changes in degranulation and cell migration occurred in a dose-dependent manner. These results indicated that these agents protected PMNs exposed to a magnetic field, and the damage to the cells that is mediated by magnetic field-stimulated Ca2+ influx might be preventable. In this regard, pharmaceutical agents might prove useful in protection against injurious electromagnetic field exposure.
...
PMID:Use of calcium channel antagonists as magnetoprotective agents. 232 Jul 22
The working hypothesis of many studies of shock has been that naloxone acts by blocking centrally and/or peripherally located opioid receptors. At plasma concentrations used to treat experimental shock (10(-6) M and above), naloxone inhibited the in vitro release of superoxide (O2-) by human neutrophils that were stimulated by the E. coli peptide N-formyl methionyl leucyl phenylalanine (FMLP). Superoxide release stimulated by phorbol 12,13-dibutyrate (PDB) was also inhibited by naloxone. Naloxone had no effect on the FMLP-stimulated release of beta-glucuronidase or
lysozyme
. Naloxone had no effect on 3H FMLP receptor binding. Studies utilizing 3H naloxone revealed the presence of a ligand-specific naloxone binding site on human neutrophils with a Kd of 1.2 X 10(-5) M, which is close to the ID50 of the inhibitory effect upon O2- release (1.8 X 10(-5). Thyrotropin releasing factor (TRF) had no effect upon 3H naloxone binding or on O2- release. Verapamil, a
calcium channel
blocker, inhibited 3H naloxone binding, and O2- release while nifedipine, another
calcium channel
blocker had no effect on either assay except at 10(-4) M, at which concentration 3H naloxone binding as well as the release of O2- were increased. These experiments suggest that the inhibitory effect of naloxone upon O2- release is mediated via a specific binding site.
...
PMID:Inhibition by naloxone of neutrophil superoxide release: a potentially useful antiinflammatory effect. 302 81
The rabbit polymorphonuclear neutrophil degranulation response to 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine depends on extracellular calcium. In the absence of this bivalent cation, neutrophil suspensions pretreated with cytochalasin B responded to the lipid by releasing minimal amounts of
lysozyme
and beta-glucuronidase. Incremental increases in extracellular calcium over a range of 20-200 microM led to increasing amounts of lipid-stimulated enzyme release. In contrast, extracellular magnesium neither supported nor enhanced the degranulation responses. Verapamil (25-200 microgram/ml), a
calcium channel
blocker, inhibited degranulation. Neutrophil suspensions exposed to the phosphocholine stimulus rapidly took up radiolabeled extracellular calcium. The kinetics of this calcium uptake were similar to the kinetics of enzyme release, and the amount of calcium taken up correlated closely with the amount of released
lysozyme
and beta-glucuronidase. Finally, in a dosage which blocked degranulation, verapamil inhibited calcium uptake. Thus, the rapid association of extracellular calcium with the neutrophil may mediate, at least in part, the degranulating actions of the phosphocholine stimulus.
...
PMID:Role of extracellular calcium and neutrophil degranulation responses to 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. 627 Oct 16